US-based biotechnology firm Luminex has launched a new NxTAG Respiratory Pathogen Panel (RUO) test, which enables laboratories to simultaneously detect 22 respiratory pathogens in a single closed tube system.
The assay accommodates higher throughput required to respond to seasonal changes in demand.
Luminex president Homi Shamir said: "Luminex introduced multiplexed respiratory panels to the clinical market in 2008 and our customers are anxiously awaiting a next-generation product that delivers expanded panel coverage and a simple closed tube workflow, combined with the throughput and quality of results established by the xTAG Respiratory Viral Panel.
"We are also pleased to report that we remain on track with our NxTAG clinical trials schedule which started in the first quarter of the year, and we expect the FDA submission to occur in the summer of 2015."
The new respiratory assay needs only a few minutes and no upstream reagent preparation, while extracted samples are added directly to pre-plated, lyophilised reagents.
With the help of Luminex MAGPIX instrument, the tubes are then sealed to prepare for closed tube amplification and subsequent detection.
The new tube strip design enables laboratories to manage variable sample demand as it helps in processing a single sample or up to 96 samples per run without wasting consumables or reagents.
Capable of incorporating NxTAG easily into any laboratory, the accompanying SYNCT Software offers a comprehensive approach to data analysis and reporting.
According to the company, clinical trials for NxTAG are currently being carried out in the US.
Image: NxTAG allows testing for 22 respiratory targets with a closed tube system and an easy three-step workflow. Photo: courtesy of Luminex Corporation.